If you’re wondering whether psilocybin therapy works for depression, the human research so far is promising but early. A 2023 meta-analysis in Psychiatry research found a large pooled effect in favour of psilocybin on depression severity, and its authors describe the findings as preliminary.
Psilocybin is being studied as a possible treatment. In the 2024 JAMA Network Open trial, it was given in a medication session with two preparation visits and three integration visits. Whether it could fit your situation is a question for a clinician who knows your history.

Does psilocybin therapy work for depression?
The clearest summary is a 2023 meta-analysis in Psychiatry research, indexed by PubMed. It pooled 9 studies with 596 people and found “a large effect size in favour of psilocybin” on depression severity. Plainly put, this is early human research: small trials, and summaries of them that the authors themselves describe as preliminary.
What the main studies found
| Study | Who took part | What it reports |
|---|---|---|
| 2023 meta-analysis, Psychiatry research (PubMed) | 9 studies pooled, 596 people with major depressive disorder or a life-threatening illness | Standardized mean difference of -0.78 in favour of psilocybin (p<0.001). Response and remission rates were significant in favour of psilocybin. |
| 2023 dose-response meta-analysis, European Neuropsychopharmacology (PubMed) | 7 randomized placebo-controlled trials, 489 adults with primary or secondary depression | Dose values differed by group. The authors say the optimal dosage for depression “remains unclear” and that more randomized trials are needed. |
| 2022 trials, Nature Medicine (PubMed) | An open-label trial in treatment-resistant depression, and a double-blind trial in major depressive disorder comparing psilocybin with the antidepressant escitalopram | Response to psilocybin was rapid and sustained, and linked to greater global connection between brain networks. The escitalopram response was milder, with no change in network organization. |
| 2024 randomized trial, JAMA Network Open (PubMed) | 30 clinicians with moderate to severe depression after frontline COVID-19 work, 15 per arm, compared with niacin | Depression scores on the MADRS scale changed by an average of -21.33 with psilocybin and -9.33 with niacin, a difference of -12.00 (95% CI -17.67 to -6.33; P<.001). The burnout change was not statistically significant. |
The 2022 Nature Medicine work is the one that looked at the brain. Its authors propose that psilocybin’s antidepressant action “may depend on a global increase in brain network integration.” For more on that, read our psilocybin brain effects page.
Psilocybin dose for depression: what is known
The 2023 dose-response meta-analysis in European Neuropsychopharmacology pooled seven trials and found that the best dose differed between groups of patients. Its authors call for more randomized trials in each group to set the optimal dosage. No dose is given on this page, because choosing one is a decision for a clinician.
Side effects and who may not qualify
The same 2023 dose-response analysis found significant dose-response associations for several side effects. The table lists them as the authors reported them.
| Side effect | What the 2023 dose-response analysis reports |
|---|---|
| Physical discomfort | Significant dose-response association |
| Blood pressure increase | Significant dose-response association |
| Nausea or vomiting | Significant dose-response association |
| Headache or migraine | Significant dose-response association |
| Prolonged psychosis | Significant dose-response association, named as a risk |
Trial eligibility shows who researchers keep out. The USF Health page for a Compass psilocybin study in PTSD excludes people with a history of bipolar disorder, psychotic disorders or borderline personality. Its generalized anxiety study also excludes current or past PTSD, schizophrenia and schizoaffective disorder. Safety and efficacy are still being studied, according to the 2023 Psychiatry research analysis, and you can read more on our psilocybin long-term effects page.
Psilocybin for depression and anxiety
As of November 2026, USF Health says its researchers are investigating psilocybin and similar psychedelics as potential treatments for treatment-resistant major depressive disorder, postpartum depression and other depressive conditions. For anxiety, the same USF Health page lists a generalized anxiety disorder study of RE104, an investigational psychedelic medication, compared with placebo. The page names RE104 separately from psilocybin.
Cannabis is often suggested for anxiety too. Cleveland Clinic’s September 10, 2024 article on marijuana and mental health describes the research for anxiety as low-grade, and it says the products can make anxiety and panic worse in some people. Ask your clinician before you consider it.
What to do when therapy and medication haven’t worked
The USF Health page describes its depression research as aimed at depression that is “not easily treated with medication or other standard therapy.” Studies call this group treatment-resistant depression.
Some trials set a bar for who joins based on past treatment. The USF Health anxiety study ITI-1284 lists an inadequate response to at least two of paroxetine, venlafaxine XR, duloxetine, escitalopram or buspirone. Bring a list of what you have tried, how long each lasted and what happened to your symptoms to your clinician. That list is what should guide the next step.
Ways to manage depression besides psilocybin
Cleveland Clinic’s article says that if you’re struggling with anxiety or depression, your best option is to speak with your healthcare provider about the many more well-studied and successful ways to treat these conditions. The options below are the ones the sources on this page discuss.
| Option | What the research shows | Limits and who should be careful |
|---|---|---|
| Psilocybin in a trial setting | Lower depression scores in the trials listed above | Investigational. Trials exclude some diagnoses, and safety and efficacy are still being studied. |
| Escitalopram, an antidepressant | Used as the comparison drug in a 2022 Nature Medicine trial, where its response was milder than psilocybin’s | Decide with your clinician, who knows your history and current prescriptions. |
| ITI-1284, an investigational anxiety drug | Being studied in a generalized anxiety disorder trial at USF Health | Trial enrollment only, with eligibility rules set by the study. |
| Cannabis and THC products | Cleveland Clinic says cannabis isn’t recommended to treat mental health disorders, and a 2019 review of 83 studies found no compelling support for it in mental health treatment | Can make anxiety, depression and panic worse in some people, and carries an addiction risk |
| Lion’s mane mushroom | MSKCC reports limited clinical data on mood and memory, including mood in menopausal women. Long use in East Asian and Native American medicine for anxiety, stress and depression is also described by MSKCC. | Abdominal discomfort, nausea and skin rash were reported in a clinical study. See our lion’s mane mushroom benefits (our research library) page. |
| Mushroom and herbal supplements | The NIH’s NCCIH says supplement labels cannot claim that a product diagnoses, treats or prevents any disease | Quality varies, and the NCCIH notes that what is on the label may not be what is in the product |
For a broader look at mushrooms and mood, see our mushrooms and mental health guide.
Is a mushroom product for mood safe?
The FDA’s December 18, 2024 constituent update on Amanita muscaria says that the mushroom and its constituents are not authorized for use in conventional food, and it recommends that people avoid eating foods with these ingredients. Some of these products are marketed as “psychedelic edibles.” That alert covers Amanita muscaria, not psilocybin, but it is a useful warning about the “psychedelic” label on mushroom products.
What is not known yet
- The right dose. The 2023 dose-response analysis says the optimal dosage remains unclear.
- Safety and efficacy. The 2023 Psychiatry research analysis says further studies are needed to evaluate safety and efficacy and to optimize treatment protocols.
- Whether psilocybin is approved as a depression treatment. As of November 2026, USF Health describes its psilocybin work as research into potential treatments, so check the current status at fda.gov.
- How untreated depression affects you over many years, or whether it can damage the brain. Ask your clinician.
Before you decide
- Ask your clinician whether a psilocybin trial fits your history, your diagnoses and your current medicines.
- Ask the trial coordinator about eligibility, the number of visits, cost and who supervises the sessions.
- If you’re asking about microdosing, bring that question to a clinician, since the trials above are scheduled sessions.
- For USF Health trials, the listed contact is Yvonne Bannon at ybannon@usf.edu or (813) 974-2832.
By MushroomHealthBenefits.com Research & Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.